TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) S.A.E. Financials Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
Equities
RMDA
EGS381B1C015
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.3 EGP | -0.43% |
|
-0.86% | +39.39% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,543 | 2,928 | 2,400 | 2,892 | 2,459 | 3,428 | - | - |
| Enterprise Value (EV) 1 | 3,637 | 3,339 | 2,761 | 2,892 | 3,223 | 4,495 | 4,286 | 3,818 |
| P/E ratio | 43 x | 30 x | 14.4 x | 12.9 x | 11.1 x | 11.5 x | 6.29 x | 5.1 x |
| Yield | - | - | - | - | - | 4.61% | 7.65% | - |
| Capitalization / Revenue | 3.96 x | 3.05 x | 1.93 x | 1.95 x | 1.28 x | 1.23 x | 0.97 x | 0.87 x |
| EV / Revenue | 4.07 x | 3.48 x | 2.21 x | 1.95 x | 1.68 x | 1.61 x | 1.22 x | 0.96 x |
| EV / EBITDA | 14.3 x | 13.7 x | 8.63 x | 6.83 x | 6.05 x | 5.81 x | 4.14 x | 3.24 x |
| EV / FCF | 51.7 x | -9.14 x | - | - | -10.8 x | 12.8 x | 15.4 x | 9.92 x |
| FCF Yield | 1.93% | -10.9% | - | - | -9.25% | 7.83% | 6.47% | 10.1% |
| Price to Book | 3.3 x | 2.47 x | 1.78 x | - | 1.4 x | 1.76 x | 1.52 x | 1.08 x |
| Nbr of stocks (in thousands) | 1,522,533 | 1,522,533 | 1,522,534 | 1,482,613 | 1,490,530 | 1,490,530 | - | - |
| Reference price 2 | 2.327 | 1.923 | 1.576 | 1.951 | 1.650 | 2.300 | 2.300 | 2.300 |
| Announcement Date | 2/18/20 | 3/2/21 | 2/24/22 | 3/7/23 | 3/19/24 | - | - | - |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 894 | 960.2 | 1,246 | 1,484 | 1,922 | 2,793 | 3,522 | 3,960 |
| EBITDA 1 | 253.5 | 243.9 | 319.8 | 423.2 | 532.9 | 774.1 | 1,035 | 1,180 |
| EBIT 1 | 217.3 | 187.6 | 273.6 | 357.7 | 440.1 | 613.4 | 949.5 | 1,207 |
| Operating Margin | 24.31% | 19.54% | 21.95% | 24.11% | 22.89% | 21.96% | 26.96% | 30.47% |
| Earnings before Tax (EBT) 1 | - | 145.1 | 233.6 | 328.5 | 327.4 | 414.3 | 732 | 908.4 |
| Net income 1 | - | 112.2 | 181.1 | 245.7 | 244.9 | 360 | 534 | 716 |
| Net margin | - | 11.68% | 14.53% | 16.56% | 12.74% | 12.89% | 15.16% | 18.08% |
| EPS 2 | 0.0541 | 0.0640 | 0.1093 | 0.1518 | 0.1489 | 0.1998 | 0.3659 | 0.4508 |
| Free Cash Flow 1 | 70.35 | -365.4 | - | - | -298 | 352 | 277.5 | 385 |
| FCF margin | 7.87% | -38.06% | - | - | -15.5% | 12.6% | 7.88% | 9.72% |
| FCF Conversion (EBITDA) | 27.75% | - | - | - | - | 45.47% | 26.8% | 32.64% |
| FCF Conversion (Net income) | - | - | - | - | - | 97.78% | 51.97% | 53.77% |
| Dividend per Share 2 | - | - | - | - | - | 0.1060 | 0.1760 | - |
| Announcement Date | 2/18/20 | 3/2/21 | 2/24/22 | 3/7/23 | 3/19/24 | - | - | - |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2023 S2 |
|---|---|---|---|---|---|
| Net sales 1 | 450.4 | 842.4 | 542.7 | 534.2 | 1,080 |
| EBITDA 1 | - | - | - | 140.7 | - |
| EBIT | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income 1 | 49.16 | 115.7 | 71.6 | 52.9 | 129.2 |
| Net margin | 10.91% | 13.73% | 13.19% | 9.9% | 11.96% |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/15/23 | 8/15/23 | 11/14/23 | 3/19/24 | 3/19/24 |
1EGP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 93.4 | 410 | 361 | - | 763 | 1,067 | 858 | 390 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.3682 x | 1.683 x | 1.127 x | - | 1.433 x | 1.378 x | 0.8288 x | 0.3305 x |
| Free Cash Flow 1 | 70.3 | -365 | - | - | -298 | 352 | 278 | 385 |
| ROE (net income / shareholders' equity) | 10.8% | 9.94% | 14.3% | 17.3% | 14.9% | 16.1% | 23.6% | 23.8% |
| ROA (Net income/ Total Assets) | 5.39% | 5.45% | 7.76% | 9.57% | 8.17% | 11% | 11% | - |
| Assets 1 | - | 2,058 | 2,335 | 2,567 | 2,996 | 3,273 | 4,855 | - |
| Book Value Per Share 2 | 0.7000 | 0.7800 | 0.8900 | - | 1.180 | 1.310 | 1.520 | 2.120 |
| Cash Flow per Share 2 | 0.0400 | -0.1100 | 0.1600 | 0.0200 | -0.0300 | -0.0700 | -0.0100 | 0.5400 |
| Capex 1 | 90.8 | 201 | 238 | 128 | 253 | 110 | 220 | 258 |
| Capex / Sales | 10.16% | 20.95% | 19.11% | 8.64% | 13.19% | 3.94% | 6.25% | 6.52% |
| Announcement Date | 2/18/20 | 3/2/21 | 2/24/22 | 3/7/23 | 3/19/24 | - | - | - |
1EGP in Million2EGP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.3
EGP
Average target price
4.41
EGP
Spread / Average Target
+91.74%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +39.39% | 71.8M | |
| +61.53% | 856B | |
| +38.95% | 631B | |
| -3.66% | 359B | |
| +15.06% | 325B | |
| +9.18% | 297B | |
| +5.89% | 234B | |
| +16.53% | 226B | |
| +15.67% | 177B | |
| +2.47% | 165B |
- Stock Market
- Equities
- RMDA Stock
- Financials Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
